Assessment of Injection Behavior of Commercially-available Bone BSMS for Subchondroplasty Procedures by Colon, Dinely A
City University of New York (CUNY) 
CUNY Academic Works 
Dissertations and Theses City College of New York 
2015 
Assessment of Injection Behavior of Commercially-available Bone 
BSMS for Subchondroplasty Procedures 
Dinely A. Colon 
CUNY City College 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/cc_etds_theses/821 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Assessment of Injection Behavior of Commercially-









The City College of New York 
Of the 
City University of New York 
By 
Dinely A. Colon 
 




                __________________________________________ 
Professor Mitchell B. Schaffler, Thesis Advisor 
 
_________________________________________ 
Professor Mitchell Schaffler, Chairman 






















© Copyright 2015 





This thesis is dedicated to my beloved family. Thank you Mom and Dad for your 
unconditional love and support, you are my rock and inspiration. Thank you to my brother Abel 
and my sister Viandy, you guys are always there for me and never let me fail. Thank you to all 
the people who I came across during my academic training, because you enhanced my 
knowledge in one way or another. Lastly, thank you to all my friends for their unconditional love 






I would like to thank my defense committee Dr. Barry Nicoll and Dr. Mitchell Schaffler 
from the Biomedical Engineering Department at the City College of New York. Also, a big 
thanks to my advisor Dr. Celeste Abjornson for her support and guidance during this project and 
for allowing me the opportunity to work in such a prestigious institution such as the Hospital for 
























Table of content 
List of Tables……………………………………………………………………………………vii 
List of Figures……………………………………………………………………………….…viii 
Abstract…………………………………………………………………………………………..x 
CHAPTER 1. Introduction……………………………………………………………………...1 
1.1 Anatomy of the Knee………………………………………………………………….4 
1.2 Subchondral bone……………………………………………………………………...5 
1.3 Disruption of the integrity of the knee………………………………………………...7 
1.3.1 Osteochondritis……………………………………………………………8 
1.3.2 Bone Marrow Lesions (BMLs)……………………………………………9 
1.3.3 Osteoarthritis …………………………………………………………….10 
1.3.4 Bone Necrosis……………………………………………………………11 
1.4 Treatment Methods…………………………………………………………………..12 
1.4.1 Subchondroplasty………………………………………………………...13 
1.5 Bone Cements………………………………………………………………………..14 
1.6 Bone Substitute Materials (BSMs)…………………………………………………..15 
1.6.1 CaP……………………………………………………………………….16 
1.7 Bioactive Fiber Glass………………………………………………………………...17 
CHAPTER 2. Material and Methods 
2.1 Preparation of the foam blocks………………………………………………………18 
2.2 Preparation of BSMs…………………………………………………………………18 
2.3 Mechanical testing for the injection………………………………………………….19 
2.4 Preparation of AccuaFill with bioactive fiberglass 4S5……………………………..20 
2.5 Compression strength of AccuaFill with bioactive fiberglass 4S5 and glass bead 
particles…………………………………………………………………………………..21 
2.6 SEM Microscopy of AccuFill with bioactive 
components……………………………………………………………………………....21 
2.7 Measure dry, cure weight…………………………………………………………….21 
2.8 Injection into cadaveric bones……………………………………………………….22 
2.9 Micro CT Scan……………………………………………………………………….22 
2.10 Statistical Analysis………………………………………………………………….23 
 
CHAPTER 3. Results 
3.1 Mechanical testing of the injection for the commercially available BSMs………….23 
3.2 Measurements of net weight for commercially available BSMs…………………….26 





3.4 Cadaveric Samples…………………………………………………………………...31 
3.5 Mechanical testing of the injection force of AccuFill with the bioactive fibers and  
beads…………………………………………………………………………………32 
3.6 Weight measurements of AccuFill with the bioactive fibers and beads……………..34 
3.7 Micro CT Scan evaluation of AccuFill with the bioactive fibers and beads………...35 
3.8 Compression strength of AccuFill with the bioactive fibers and beads……………...37 
3.9 SEM Microscopy…………………………………………………………………….39 
 
CHAPTER 4. Discussion……………………………………………………………………….40 
 4.1 Future Approach…………………………………………………..…………………45 
CHAPTER 5. Conclusion………………………………………………………………………46 






















List of Tables 
Table 1. Evaluated Bone Substitutes Materials and their Manufacturer’s described properties...17 



























List of Figures 
Figure 1:  The main components of the knee joint. 1) Hyaline articular cartilage. 2) Patella (knee 
Cap). 3) Menisci. 4) Femur. 5) Anterior/Posterior Cruciate Ligament. 6) Tibia. 7) Fibula. 8) 
Lateral Collateral Ligament. 9) Medial Lateral Ligament. 10) Patellar Tendon. 11) Quadriceps 
Muscles…………………………………………………………………………………………5 
Figure 2: Subsequent description of the different layers of tissue present in the knee joint……7 
Figure 3: Cartoon representation of the OCD condition in the knee joint……………………...9 
Figure 4: Cartoon representation of a healthy and an osteoarthritis disease knee joint……….10 
Figure 5: Bone marrow lesion in the knee joint……………………………………………….11 
Figure 6: Suchondroplastic procedure, cause, and outcome. A) Surgical set up of the 
subchondroplastic procedure. B) Lesion in the subchondral bone. C) Lesion area filled with a 
BSM after debridement. D) Totally healed sudchondral bone after a subchondral 
procedure………………………………………………………………………………………14 
Figure 7: The mechanical testing setup utilized showing all the components of the bone cement 
delivery method………………………………………………………………………………..21 
Figure 8: Image of one of the AccuFill samples within the simulated trabecular bone in a full 
view and cut at the zero plane…………………………………………………………………24 
Figure 9: Injection force evaluation of some of the commercially available bone cement. A) 
Average Maximum Injection force (Kgf). B) Mean Injection Forces for each syringe run of all 
materials tested………………………………………………………………………………..26 
Figure 10: Net weight measurements of the common commercially available bone cement that 
were tested. Data is presented as the mean and standard deviation with a p<0.001 for significant 
difference……………………………………………………………………………………..30 
Figure 11: Representative micro-CT reconstructions of each BSMs material. Micro-CT image of 
the foam samples both as a whole and cut at the zero-plane…………………………………31 
Figure 12: Commercially available BSM volume per tissue/foam volume (CV/TV …..…….32 
Figure 13: Coefficient of determination………………………………………………………32 
Figure 14:  Micro CT images of humans’ cadaveric samples that were injected with either 





Figure 15: Mean injection force evaluation of AccuFill bone cement with bioactive fibers and 
glass beads particles at different percentages. Data is presented as mean and standard deviation 
with (p<0.05) for significant difference…...………………………………………………….35 
Figure 16:) AccuFill combine with different percentages of bioactive fibers or beads. Data is 
presented as the mean and standard deviation with a (p<0.05) for significant difference........36 
Figure 17: Representative micro-CT reconstructions of AccuFill bone cement with bio-glass 
fibers and beads particles at different percentages. Micro-CT image of the foam samples both as 
a whole and cut at the zero-plane…………………………………………………………….37 
Figure 18: AccuFill bone cement with bio-glass fibers and beads at different percentages volume 
per tissue/foam volume (CV/TV). Data is presented as the mean and standard deviation with a 
(p<0.05) for significant difference.…………………………………………………………..38 
Figure 19: Compressive strength test measuring the stress at maximum load (MPa). Effects of 
%wt of bioactive fibers in AccuFill cement. Data presented as mean and standard deviation for 
n=5.  Data is presented as the mean and standard deviation with a (p<0.05) for significant 
difference.…………………………………………………………………………………….40 









 Subchondroplasty is a procedure that utilized bone substitutes materials (BSMs) or bone 
cement to correct bone defects in the subchondral bone. The two main materials used to compose 
BSMs are poly-methyl-methacrylate (PMMA) and calcium phosphate cement (CaP). Currently, 
there is no optimal bone material substitute in the market that can provide both the adequate 
mechanical support and the right viscosity to reach the affected area in the subchondral bone. In 
addition, there is also no established parameter for their proper use, based on the defect size and 
location. PMMA possesses comparable mechanical properties to bone (i.e. 96 MPa in 
compressive strength) but does not promote bone formation. Meanwhile, CaP possesses 
biocompatibility and degradability properties but as a material, has weak compression strengths 
(i.e. 6 MPa) and no shear strength. The objective of this study was to evaluate the in vitro 
injectability of several common commercially available BSMs into a simulated trabecular bone 
model. The aim was to evaluate the performance of eight commercially available BSMs, 
(AccuFill®, Simplex™, StrucSure™, Beta BSM™, Cerament™, Hydroset™, Norian™ SRS, 
Pro-Dense®)  including the force required to deliver the bone substitute into the simulated 
cancellous bone (PVF 12.5 polyurethane foam), the amount of BSM injected, and the flow 
pattern in a closed void. Thus far, we found that the CaP-based AccuFill was the only cement 
that was easily delivered (i.e. lowest injection force), in sufficient volumes, and easily filled the 
affected area without damaging the host structure (p<0.001). In an attempt to enhance the 
mechanical properties of the CaP-based AccuFill, we mixed AccuFill with different weight 
percentage ratios of bioactive glass fibers and beads. Overall, adding bioactive components to 
AccuFill did not affect injection force and delivery of material (p<0.05). Adding 10% wt glass 
fibers increased compressive strength of the new BSM by 15%.   This study is the first to 





flow behavior and mechanical strengths within simulated cancellous bone structures.  Data from 
this study can be used to further analyze the feasibility of future BSM composites to improve 





CHAPTER 1: INTRODUCTION 
Orthopedic surgery often requires bone substitute materials (BSMs) for filling bony defects, 
prosthesis fixation, and fracture fixation. There are many categories of materials that are 
characterized as BSMs for surgical usage varying in composition, strength, and application. In 
general, BSMs have been designed to fill open voids or gaps in a macro-environment under little 
to no pressure. Many materials are described as moldable and can be manually placed. The most 
widely used classic bone cement is poly (methyl methacrylate) (PMMA) and most widely used 
BSMs are calcium phosphate (CaP) based. PMMA is indicated for the fixation of prostheses, 
fixation of fractures, and void filling for reinforcement of living bone during orthopedic 
procedures [18,12,25]. PMMA is known for its strength and permanence, but unpopular for its 
handling properties and the peripheral damage to the living bone during the exothermic setting 
reaction [45,39]. Use of PMMA in primary surgical interventions also possesses complications 
for future secondary surgeries. Calcium phosphates (CaPs) have come into favor for their ability 
to form a bioactive apatite compound similar to bone mineral inducing bone formation. They 
also have improved handling properties that result in a paste-like material which can be injected 
or molded into non-weight-bearing defects. Calcium phosphate BSMs can crystallize at body 
temperature without any adverse effect in the host area [22,45]. 
In general, BSMs differ from classic bone cements not only in their composition but also in 
their intended method of action. They are designed to be osteoconductive and resorbable [14]. 
For example, CaPs can be partially resorbed by osteoclastic elements, releasing in the process 
calcium and phosphate ions, which are promoters of bone apposition [6]. This quality makes 
calcium phosphate an osteoconductive ceramic by nature with a good biocompatibility specific 
for bone [43]. How the BSM behaves during the healing process depends both on the properties 





combination of the powder and liquid form of the bioactive and biodegradable bioceramics, 
forming a paste that can be molded to fit the affected area. When hard, this mixture yields a non-
stoichiometric calcium-deficient hydroxyapatite or brushite [55]. 
Osseous defects, whether surgically created or as a result of a traumatic event, can present 
throughout the skeletal system as open fractures, large bony gaps, or surgically created defects 
surrounding implants. Another, unique type of defect is one in which the defect is within the 
microarchitecture of the trabecular bone but the cortical shell remains intact, presenting as a 
closed void or fracture with an innate small, interconnected structure. For example, when 
abnormal loading occurs in diarthrodial joints, internal stress fractures can occur in the 
subchondral bone, termed bone marrow lesions (BMLs). This is a painful condition, especially in 
the case were damage exceed the capability of a normal repair process. Physiologically, as the 
damage increases in the subchondral area so is the repair response resulting in small focal 
regions of hard, sclerotic bone. At the junction of the sclerotic bone with the surrounding weaker 
bone, significant changes in forces can be sense altering the balance between rap repair/damage 
resulting in even more damage to the tissue. 
BMLs are identified on MRI rather than x-ray, and are sometimes called bone marrow edema 
(BME) due to their edema-like appearance on imaging. Micro CT scan can be used to evaluated 
the areas that have been identify as BMLs. It has been shown that this technique can help 
identify abnormalities such as bone morrow necrosis, bone morrow fibrosis and trabecular 
abnormalities in the tissue affected by this lesions. Histologic analysis of BMLs have shown 
micro-trabecular damage characteristic of a stress or insufficiency fracture. In this situation, there 
are micro-fractures within the architecture of the trabecular bone. The surgical placement of 





environment with the innate increased risk of damage to surrounding tissue [22]. The ideal 
surgical technique utilizes a minimal entry point to preserve the cortical bone integrity while 
being able to deliver enough BSM to treat the defect without allowing any leakage outside the 
affected area.  
Bone cements such as PMMA are readily manipulated to change their viscosity at the 
expense of their set up time, whereby less viscous materials take longer to cure. In contrast, the 
biphasic nature of CaP BSMs requires a specific mixture such that their viscosity is not easily 
manipulated for the application. Understanding the BSM injection behavior and accurately 
predicting the BSM placement and volume within the trabecular space could offer significant 
clinical guidance. As there is no standardized model for the subchondral bone of the knee, we 
propose utilizing standardized polyurethane block material that has been shown to behave similar 
to the trabecular bone of the knee to examine the BSM injection behavior. We hypothesize that 
many BSMs are only injectable in large microarchitectures and would fail to function in a small 
microarchitecture environment. The objective of this study was to evaluate the in vitro 
injectability of 8 common commercially available BSMs into a simulated trabecular bone model.  
It was hypothesized that some materials, self-described as “injectable”, would be able to fill large 
bone voids, but they would fail to function in a small microarchitecture. To test this hypothesis 
we applied a mechanical evaluation of the injection (injection force vs. cement composition). In 
addition, we determined the amount of mass deliver into the sawbones model and correlated to 
the cement volume obtain from a micro CT scan. The micro CT scan was also used for the flow 
evaluation within the simulated cancellous bone. 
After comparing the 8 commercially available bone substitute’s material that varies in 





close environment. Due to these results, a new question was addressed; can we improve the 
mechanical strength of this material without affecting the flow of the cement into the closed void 
by adding bioactive components? In order to answer this question AccuFill was chosen for 
characterization using different weight percent (wt %) of bioactive fiberglass (45S5) and glass 
beads of different sizes in an attempt to enhance its weak mechanical compressive strength. The 
aim was to investigate the mechanical evaluation of the injection (injection force vs. AccuFill 
combine with bioactive fibers and beads at different weight percentages), as well as the weight, 
injection pattern, and compression strength. Finally, a SEM microscopy evaluation was 
performed in order to evaluate the distributions of the bioactive fiber glass and glass beads 
particle in the AccuFill cement. 
1.1 Anatomy of the knee 
The human knee consists of four bones: the patella, femur, tibia, and the fibula, which are 
attached to each other by tendons and ligaments. Each of these bones has a unique architecture 
and function that allows for joint stability. The bones are protected by a layer of hyaline articular 
cartilage at the joint side [5]. The knee joint has two articulations: the femur-tibia and the femur-
patella. These articulations are stabilized by the menisci, which lies between the condyles, 
(medial and lateral), and the tibia plateau. The knee joint has the unique ability to allow 
movement by flexion and extension while carrying the body weight [15].  The knee is the largest 
joint in the body and can resist load peaks up to 5-8 times the body weight [22]. In the long 
bones, such as the femur and the tibia, one can find the subchondral bone under the hyaline 
cartilage layer as well as in the inner region of the patella bone. For purpose of this paper, the 







Figure 1. The main components of the knee joint. 1) Hyaline articular cartilage. 2) Patella (knee 
Cap). 3) Menisci. 4) Femur. 5) Anterior/Posterior Cruciate Ligament. 6) Tibia. 7) Fibula. 8) 
Lateral Collateral Ligament. 9) Medial Lateral Ligament. 10) Patellar Tendon. 11) Quadriceps 
Muscles. 
1.2 Subchondral bone 
 
In a natural joint, articular cartilage, in combination with the subchondral bone acts as a 
mechanical load bearing system. The combination of those two components is what allows the 
joint motion, stability, and the evenly distribution of high loads [60]. Subchondral bone is 
composed of subchondral plates and subchondral trabecular bone. Subchondral plates are 
composed of cortical lamellar bone. This bone lies right under the calcified articular cartilage in 
the joints, followed by the subchondral trabecular bone. The subchondral trabecular bone gives 
rise to a more defined trabecular bone [17].  Subchondral trabecular bone is responsible for 
shock absorption due to the increase in porosity. It is also highly vascularized, and contains 
sensory nerves and bone marrow. These properties differentiate the subchondral trabecular bone 
form the subchondral plate [17,48]. Due to the inhomogeneity in the subchondral bone, this bone 





consequence of the local high incidence of bone turnover [17,44]. The overall function of the 
subchondral bone is to provide support to the overlying articular cartilage and to distribute 
mechanical loads in the joints [17,33]. The plates in this lamellar bone are relatively thick (0.2-
0.4 mm) and the space is relatively narrow (0.4-0.6 mm) [12]. This bone is mainly composed of 
type II collagen and it is connected by the collagen cross link to the articular cartilage. Its 
composition and location allows transformation of shear forces during compression and traction 
(Figure 1), [19]. The subchondral bone possesses an elastic modulus that ranges from 1-15 MPa 
[60,32], and has the ability to attenuate about 30% of the loads through the joints, which is a lot 
more than in cartilage with only 1-3% attenuation [19,58].  The integrity of the subchondral bone 
can be affected by: obesity, gender, age, physical activity, previous joint injury, joint 
misalignment, abnormal joint shape and genetic predisposition which can lead to the 






Figure 2. Subsequent description of the different layers of tissue present in the knee joint.  
1.3 Disruption of the integrity of the Subchondral Bone 
 
Chondral integrity is mainly affected by: injury, pathologic loading and aging [26]. Hyaline 
articular cartilage defects are thought to increase stresses in the subchondral bone. In his article, 
Cox et al. (2011) investigated this behavior and found that this damage may induce bone 
remodeling [30]. Meanwhile, Harada et al. (1988) showed that the strength of the subchondral 
bone varies depending on the sex (male to female), location (medial condyle or lateral condyle), 
age, and the overall density of the bone [19,62]. Males under the age of 50 are more susceptible 
to develop osteoarthritis that subsequently affects the subchondral bone than females of the same 





than males [17]. The medial condyle is more susceptible to damage than the lateral condyle due 
to the mechanical loads that it experiences [30]. Furthermore, this load generates micro-cracks in 
order to ignite bone remodeling process. The high rate of bone turnover and the formation of the 
micro-cracks lead to the thickening of subchondral plates and eventually causes cartilage 
thinning [17]. The thickening of the subchondral bone results in structural and mechanical 
changes of the joint [19]. Both cartilage and the subchondral bone are affected by a variety of 
diseases, such as traumatic osteochondral defects, osteochondritis dissecans, osteonecrosis, and 
osteoarthritis [18]. The following sections will describe these diseases process in depth. 
1.3.1 Osteochondritis 
Osteochondritis is the separation of cartilage region from the bone (Figure 3) [12]; it can 
also be classified as a separation of components in the joint [8]. This condition can be caused by 
hereditary pre-disposition, vascular insufficiencies, ephyseal abnormality, and trauma. This is a 














1.3.2 Bone Marrow Lesions (BMLs) 
BMLs is a healing response to micro fractures caused by chronic overload in bone [15]. It 
appears in the weight bearing regions of the knee such as the tibia plateau and the femoral 
condyles, but their pathology is not well understood (Figure 4), [22,25]. Various authors had 
reported that BMLs appeared in tissue with a combination of chronic and remodeling patterns 
resulting in either fibrosis, necrosis, or in focal osseous collapse [15,38,50]. This can lead to the 
deformity of the osseous articular contour [15]. The increase in load causes an increase in the 
stress sense in the bone, causing micro fractures [15,13]. Over time, this lesions get larger in 
sizes, becoming more difficult to be eliminated by the body and resolve. The bone affected by 
BMLs, decreases in stiffness, which gives rise to a cascade of further degradation and 







                                                                                                                                                                    
 








1.3.3 Osteoarthritis  
Osteoarthritis is a disease that affects the articular cartilage primary, and secondary the 
under layer of bone (Figure 4), [5].  In osteoarthritis, cartilage degeneration is thought to increase 
the stress in the subchondral bone, probably due to the joint misalignment. This could induce a 
remodeling process as a response to the changes in the bone matrix stiffness [30, 57]. Cancellous 
bone from patients suffering from this disease has shown to possess reduced material density, 
decrease in mineralization and stiffness [5]. This disease results in chronic joint pain, restriction 
of motion, popping sound with motion, and joint effusions [30]. The risk factors associated with 
the development of this disease are: genetic disposition, age, axial misalignment, trauma, and 
gender [26]. The treatments for this condition will depend on the etiology and the progression of 
the disease [12].  It has been reported that patients suffering this condition experience pain 


















1.3.4 Bone necrosis 
Subchondral bone death or bone necrosis is a condition that affects the subchondral bone and 
it is often associated with subchondral fracture and collapse [19]. The main causes that give rise 
to osteonecrosis are: injury, radiation, or chemical misbalance adjacent to the affected area [8]. It 
can be classified into three groups: primary spontaneous osteonecrosis of the knee (SPONK), 
which the etiology is unknown, secondary osteonecrosis (SON), which happens due to ethanol 
abuse and hemiglopathy (sickle cell anemia and lupus), and in conditions such as Caisson’s and 
Gaucher’s d diseases [19]. Another type of osteonecrosis is caused by postoperative knee 
(ONPK) [12].  SPONK is more common in the elderly population, and it is characterized by 
severe knee pain. It is more common in the medial condyle of the knee. SON affects a much 
younger population; it differs from SPONK in location, and pain intensity, involving mainly the 
lateral knee compartment. Meanwhile, ONPK is only presented in post-operative conditions, and 
sometimes can be confused with SPONK [13,234. This condition reflects different types of bone 
repair reactions after a bone fracture [13,53,37,9].  
Osseous defects, whether surgically created or as a result of a traumatic event, can present 
throughout the skeletal system as open fractures (bone separates), large bony gaps, or surgically 
created defects surrounding implants. Another, unique type of defect is one in which the defect is 
within the microarchitecture of the trabecular bone but the cortical shell remains intact, 
presenting as a closed void or fracture with an innate small, interconnected structure.  
1.4 Treatment methods  
The treatment varies depending on the etiology and the progression of the disease. Most of 





of the most common approaches to treat subchondral bone defects are: joint resurfacing, 
biological grafts, inorganic materials, artificial joint replacement, and tissue engineering [60].  
Joint resurfacing is also known as partial knee replacement. This is the excision of damaged 
tissue (cartilage and bone) to expose the bone marrow, which is usually accompanied by a partial 
substitution of the knee joints. The down side of this procedure is that the cartilage around the 
incision heals to a more fibrous cartilage producing a stiffer material than the native one. This 
can result in a misalignment in the joint that may lead to further issues, such as the development 
of diseases. 
Biological grafts are used for the replacement of damaged tissue with autografts. Even though 
this is the most desirable approach, there is limitation in the amount of donor tissue supply 
available. 
Inorganic Materials are materials that are derived from polyester, polylactic acid and polyvinyl 
alcohol hydrogel in order to obtain a suitable material for artificial cartilage regeneration. The 
success of this type of approach depends on the material’s properties, shape, and the size of the 
defect. 
Artificial Joint Replacement happens when the native joint is replaced by an artificial joint due to 
a severe trauma or the progression of a traumatic damage to the cartilage such as the case of 
osteoarthritis or rheumatoid arthritis [60]. An artificial joint replacement approach may give rise 
to more complications than benefits in the long run due to the bio-compatibility and wear-and-
tear properties of the artificial implant. Most patients that undergo a joint replacement may need 





 Tissue Engineer Constructs is the application of the combination of scientific and engineering 
principles toward the repair, restoration, or regeneration of living tissue [60,10]. It uses 
biomaterials and cells either separate or in combination in order to reconstruct biological tissue. 
This approach is limited by the number of successful implants in humans. The problem with this 
approach is that it is invasive, causing more morbidity to the patient and has an overall high 
financial cost.  
1.4.1 Subchondroplasty 
Suchondroplasty is a proprietary term that describes a minimally invasive surgery that 
consists in the injection of BSMs in order to correct voids or defect in the subchondral bone 
(Figure 6) [22]. The ideal surgical technique utilizes a minimal entry point to preserve the 
cortical bone integrity while being able to deliver enough BSMs to treat the defect without 












Figure 6. Suchondroplastic procedure, cause, and outcome. A) Surgical set up of the 
subchondroplastic procedure. B) Lesion in the subchondral bone. C) Lesion area filled with a 
BSM after debridement. D) Totally healed sudchondral bone after a subchondral procedure. 
1.5 Bone Cements 
Bone cements have been widely used for the fixation of prosthesis to bone. Failure to attach 
the bone-cement-implant can result in further damage to the affected area [49]. This is one of the 
reasons why the most important parameters of bone cement are their mechanical properties. The 
most widely used bone cement is poly (methyl methacrylate) (PMMA) based. This material is 
considered to be part of the first generation of polymer biomaterials (materials developed before 
1980). The main characteristic of the product in this generation are to achieve a combination of 
physical properties to match those of the host environment with a minimal toxic response 
[34,20].  PMMA materials are widely known in the orthopedic industry for their high 
compressive strength (~93 MPa) and their thermoplastic properties. Self-polymerizing PMMA 
bone cement was introduced in 1960 by Charnley, who derived the idea from dental cement with 
the help of a chemist name D. Smith [34]. PMMA cement comes in a biphasic form of two 
different phases: a powder and a liquid phase. The powder phase consists of pre-polymerized 
PMMA, using an initiator as a catalyst for the polymerization process, and a radio-pacifier 





(BaSO4 or ZrO2); the liquid phase is formed by a MMA monomer, an accelerator reagent and a 
stabilizer [34]. When these two phases are mixed, they form a paste that has sufficient 
mechanical properties for prosthesis primary fixation, but it is neither conductive nor inductive 
of bone formation. Other negative effects associated with this cementare: embolism caused by 
the extravasations of residual monomer into the blood stream; thermal necrosis of the 
surrounding bone due to the exothermic reaction of the polymerization; and detachment of the 
bone-cement or cement-prosthesis due to the shrinkage that the cement experiences during the 
polymerization [34,1,39].   
1.6 Bone Substitutes Materials (BSMs) 
Bone substitute materials (BSMs) have been commercially available for over 30 years and 
have been used extensively in orthopedic procedures.  Some BSMs are described as “flowable” 
and “injectable”.  They are generally used to fill bone gaps and voids that are surgically or 
traumatically created. BSMs provide structural support in these applications. With rising focus 
on minimally invasive surgical procedures, the range of applications in which these materials are 
injectable is of clinical interest. Their specific interest lies in their performance in closed, 
pressurized environments where there is micro-damage or abnormal bone remodeling within the 
trabecular bone. This issue arises often in the presence of bone marrow lesions of the 
subchondral bone in early onset osteoarthritis. Orthopedic surgery often requires BSMs for 
filling bony defects, prosthesis fixation, and fracture fixation. There are many categories of 
materials that are characterized as BSMs for surgical usage varying in composition, strength, and 
application. In general, BSMs have been designed to fill open voids or gaps in a macro-
environment under little to no pressure. Many materials are described as moldable and can be 





composition but also in their intended method of action. They are designed to be osteoconductive 
and resorbable [14]. How the BSMs behave during the healing process depends both on the 
properties of the material as well as the size and location of the bone defect.  
1.6.1 Calcium Phosphate cements (CaP) 
The most widely used BSMs are calcium phosphate (CaP) based. Calcium Phosphate cements 
are ceramics that appeared as part of the second generation of biomaterials. They were developed 
after 1980 by Brown and Chow for dental purpose (US patent No. 4,518,430) [3]. They are 
characterized by their ability to interact with the host tissue in a favorable manner enhancing the 
biological response [34]. They occur in both crystalline and non-crystalline form. This depends 
on the variation in composition [3,61]. Also, they undergo a progressive degradation, allowing 
new tissue to be generated and heal the affected area [34]. This material is characterized as 
injectable. It hardens within the host bone tissue as hydroxyapatite (HA) [33, 40,51]. This 
ceramic was designed to enhance the formation of apatite layer that stimulates bone tissue 
regeneration [42,7,35,59]. For example, CaPs can be partially resorbed by osteoclastic elements, 
releasing calcium and phosphate ions, which are promoters of bone apposition [6]. These 
properties result from the combination of the powder (tetracalcium phosphate (TECP) or 
dicalcium phosphate (DCPA)) composition, and liquid form of the bioactive and biodegradable 
bioceramics, forming a paste that can be molded to fit the affected area. When hard, this mixture 
yields a non-stoichiometric calcium-deficient hydroxyapatite or brushite [55]. This quality makes 
calcium phosphate an osteoconductive ceramic by nature with a good biocompatibility specific 
for bone [43]. The down side of these compositions is their low mechanical strength which have 
limited their application to a load bearing area [47]. The tensile strength of this cement is 6 to 10 





which ranges from 8-12 um in diameter. The tensile and shear stress of these cements can be 
enhanced by the use of polymers, but biodegradable polymers lack rigidity, ductility and the 
ultimate mechanical properties for a load bearing region [47,36,5528].  In an attempt to improve 
the mechanical properties of CaP, researchers have tried filler particles in order to decrease the 
porosity and crack propagation [3]. The results show that an increase in the mechanical 
properties may decrease the formation of HA affecting the bioactivity properties [52]. CaP 
cement can take between 3 to 36 months to be completely reabsorbed and replaced by natural 
bone [3].   
1.7 Bioactive glass   
Bioactive glass is classified as bioactive ceramics, which are known for their biocompatible 
and biodegradable properties [54]. They are produced from the combination of silicon oxide 
(SiO2), calcium oxide (CaO), sodium oxide (Na2O), and phosphorous oxide (P2O5), and thermal 
treatment [46]. Bioactive glass comes in different forms and shapes (ie. fibers, spheres, disks and 
beads), and can be custom made to fit a particular need.  The main parameter of a bioactive glass 
is that it should not contain hazardous components. On the contrary, it should possess calcium 
and phosphorous which are the main components in the mineral phase of bones [46]. The first 
generation of these bioactive glass materials were commercialized as 45S5 and were developed 
by Hench and Wilson around 1984 [46,20]. It comes in fibers and beads that range in the 
nanometer to micrometer scales. This is a desirable material especially for bone, because it reacts 
with the body fluid creating a bone-like material that fools the bone cells to remodel the affected 
area. Xynos et al. (2002) reported that 45S5 ionic dissolution stimulates osteoblast proliferation 
in vitro [21]. Meanwhile, Clupper et al. (2004) shows that osteoblasts attach to the surface of the 





days in vitro. In addition, they found that the tensile strength of these fibers varies with their 
length: for a 79 um long fiber the strength will range 200-340 ± 150 MPa [11]. While these 
materials are considered brittle, they can enhance the stiffness level for bone formation when 
added to a polymeric phase [54,23]. One of the most common popular ways to enhance a 
material is by the addition of fibers: this is something that it is commonly done in construction 
and other industries in order to enhance the mechanical performance of a product. 
CHAPTER 2: MATERIALS AND METHODS 
2.1 Preparation of the foam Blocks 
Commercially-available 12.5 closed-cell polyurethane foam sheets (Pacific Research 
Laboratories, Vashon Island, Washington) were acquired and cut into 1.5 x 1.5 x1.5 inch blocks. 
This foam material has been chosen because of its mechanical properties, which are pretty 
similar to those of the cancellous bone in the distal femur and proximal tibia. The 12.5 pcf foam 
possesses an average compressive strength of 2.71 x 1016  MPa and it is intended to provide a 
mechanical substitute for cancellous bone [41,9].  A 3-mm diameter hole was drilled into each 
block to accommodate an 11-gauge cannula to the depth of 0.75 inches (center of the block). The 
empty (dry) foam-cannula construct was then individually weighed. 
2.2 Preparation of the BSMs  
Eight commercially available BSMs were acquired along with the respective mixing 
instrumentation (Table 1). Each of the eight BSMs were prepared according to the 
manufacturers’ Instructions for Use (IFU), (Table 1), also including the use of any recommended 
machinery or instrumentation. 
Product 
Name  






AccuFill® Zimmer, Inc. Nanocrystalline CaPO4 
(CaP) 





Beta-BSM™ Zimmer, Inc. Nanocrystalline CaP 30 MPa 3-5 Min 2 Min 
Cerament™ Biomet, Inc. HA and CaSO4 (CaS) 0.000025 Mpa 9 Min 4 Min 
HydroSet™ Stryker® H4Ca2O6P, TTCP,  
and Na3C6H5O7 
15MPa 24 Hours 4.5 Min 
Norian™ SRS DePuy Synthes® CaP with Na  55 MPa 3-6 Min 2 Min 
Pro-Dense® Wright Medical, 
Inc. 
CaS and CaP 40 MPa 2 Hours 3-5 Min 
StrucSure™ 
CP 
Smith & Nephew 
plc 
Nanocrystalline CaP 24 MPa  24 Hours 2 Min 
Simplex™ P Stryker® PMMA 7.3 MPa 8.5 Min  2-4 Min 
Table 1. Evaluated Bone Substitute Materials and their Manufacturer’s described properties. 
2.3 Mechanical Testing for injection 
A standard 11-gauge injection cannula, 2.39 mm ID, 3.05 mm OD (Ranfac, Avon, MA) was 
inserted into the pre-drilled channel to the depth 0.75 inches into the foam block. The cannula 
and foam construct were placed in a saline bath at 37 °C for at least 10 minutes and then secured 
in a TA HD plus Texture Analyzer (Stable Micro Systems). Once prepared, each BSM sample 
was loaded into three 1 cc syringes. It should be noted that while each material was prepared to 
the manufacturer’s IFU, the materials were injected in a standardized method that in most cases 
varied from the manufacturer’s intended delivery method. 
Each filled syringe was attached to the luer lock of the cannula and injected at a rate of 2 
mm/sec into the cannula/test block assembly in sequence. The foam block was kept in a water 
bath at 37ºC during the injection process (Figure 7). Injection pressure per syringe was measured 
by a 30-kg load cell as the extrusion force/second (AccuFill® (n=5), Beta-BSM™ (n=5), 
HydroSet™ (n=5), Pro-Dense® (n=4), Cerament™ (n=5), StrucSure™ CP (n=5), Simplex™ P 
(n=4), Norian™ SRS (n=5)). In the case that the third syringe in each sample was completely 







Figure 7. The mechanical testing setup utilized showing all the components of the bone cement 
delivery method. 
 
2.4 Preparation of AccuFill with bioactive fiberglass 45S5 and glass bead particles 
The samples were distributed into four groups: 100% AccuFill cement, 0.1 % wt fibers or 
beads, 1 % wt fibers or beads, and 10% wt fibers or beads. The 45S5 bioactive fibers were put in 
an oven for 1 hr at 100ºC. Then, the weight percent was calculated based on a 7.5 g total mass of 
cement and fibers or glass beads. Also, 1 ml of NaCl was added to the 7.5 g mixture of AccuFill 
cement in order to make a paste consistency the same as instructed by the manufacturer. Then, 
the fibers or beads were added at different weight percentages. This mix was stirred for 1 minute 






2.5 Compressive Strength for AccuFill with bioactive fiberglass 45S5 and glass bead 
particles 
After loading the three 1 cc syringes with the 100 % AccuFill cement, 0.1 % wt fibers or 
beads, 1% wt fibers or beads, and the 10 % wt fibers or beads, we proceeded to push the leftover 
cement mixture into a mold using a spatula. This was the method used to create the cylinders that 
were used in the compressive strength test. When the holes were filled with the cement, two end 
bars were used to cover the holes in the mold where the cement had been placed. These bars 
were kept in place using a small drum that allows for constant pressure. Also, this drum was used 
in order to minimize the presence of air bubbles in the molds. Then, the molds with the drums 
were placed in a water bath at 37ºC for 2 hrs in order for the cement to cure under simulated 
physiological conditions. Five 6 mm x 12 mm cylinders were obtained per group. These 
cylinders were evaluated for cracking and air bubbles, before then being weighed. Each cylinder 
was then placed on the platform of a LRX 5K, LLOYD instruments machine (Lloyd Materials 
Testing, Steyning Way, PO22 9ST, UK). This procedure allowed us to obtain the maximum 
stress at the maximum load per sample at a rate of 5mm/s.  
 
2.6 SEM microscopy for AccuFill with bioactive fiberglass 45S5 
The pieces collected from the compression test were evaluated for the distribution of the 
fibers and the beads in the cement using a SEM microscopy (Zeiss Supra 55 SEM). The pellets 
were chosen randomly, soaked in alcohol and then imaged with the BSM detector in a field of 
view of 500µm. This evaluation was aimed at investigating the particle distribution in the 
AccuFill cement. 





In order to analyze the post-weight measurements after the injection, the samples were 
weighed before the BSMs were injected. After vacuum drying for 24 hrs at 37ºC, each injected 
foam block sample was measured and compared to the post injection weight in order to 
determine mass of BSMs in the foam block.  
2.8 Injection into the Cadaveric Bone 
The AccuFill®, Beta-BSM™ and StrucSure™ materials were tested in cadaveric bone 
blocks prepared from the femoral condyles of healthy donors (age 45-87). The cadaveric setup 
was used to further validate the results under the foam bone test method. Five human specimens 
were sectioned into 2.5-inch cube sections of bone. Block setup and BSM insertion were 
performed in the same manner as the simulated cancellous bone and the same protocol was 
followed for the flow pattern. 
2.9 Micro-CT Scan 
The samples were analyzed by micro-CT using the µCT 35 desktop micro-CT scanner 
(Scanco Medical AG., Zürich, Switzerland), with the evaluation program v6.5. The samples were 
segmented and reconstructed using a processing language that allowed for the selection of the 
BSMs, the cannula and the foam/bone sample. This created a better visualization of the flow 
pattern of the BSMs within the block (Figure 8). Measurements were performed by applying the 
following criteria: 55 Kvp, 145 µA, with an integrated time of 400 ms/frame and a resolution of 
37 µm. From the images obtained, we were able to acquired BSMs volume (CV); foam or tissue 







Figure 8:  Image of one of the AccuFill samples within the simulated trabecular bone in a full 
view and cut at the zero plane. 
 
2.10 Statistical Analysis 
The differences among the tested cement samples were evaluated with the use of ANOVA 
with a post-hoc, bonferroni analysis. A p-value of p < 0.001 was considered significant for the 
specific pair comparison. The data was expressed as the mean and standard deviation for all the 
BSMs available in the market. Meanwhile, a Non-Parametric Kruskal-Wallis Test was applied, p 
<0.05 was a significant difference. This allows evaluating the differences in AccuFill cement 
when combined with the bioactive fibers and beads. In the case of a statistical difference, an 
ANOVA and the Turkey Kramer procedure was applied. 
CHAPTER 3: RESULTS 
3.1 Mechanical testing of the injection for commercially available bone cement. 
In order to evaluate the BSMs’ injectability in a closed environment, 8 commercially 
available BSMs were evaluated with a mechanical test. In the clinic, BSMs are injected in a 
sequence of syringes. The amounts of cement require to fill a void depends on the defect size, 
but the amount of cement deposit in this area is dependent on the BSMs’ properties. Thus, 
measuring the injection force of each BSM according to the clinical protocol will provide a 
better understanding of the behavior of these products in a closed environment. We hypothesized 
that most commercially available bone cement will fail to function in a small microarchitecture 





simulated cancellous bone was monitored and compared. Many of the CaP BSMs were not able 
to maintain their physical properties under pressure and experienced a phase separation. 
Specifically, the liquid component separated from the powder component of the material, which 
rendered the material uninjectable, with the powder portion remaining within the injection 
syringe. This phase separation occurred with the Beta-BSM™, Pro-Dense®, Cerament™, 
HydroSet™, and Norian™ materials. In each case, the load cell reached the maximum allowable 
force (36 kgf). 
The mean injection force and maximum injection force were measured for each material. 
Within each sample, the curve of the mean and the maximum injection force were collected for 
each of the three syringes. With the first 1-cc syringe, the injection force required to inject 
Cerament™ crossed the maximum threshold. At the introduction of the second 1-cc syringe, 
Beta-BSM™, Pro-Dense®, HydroSet™ and Norian™ all reached maximum force. Although the 
test setup used a 30-kg load cell, the machine had the capability to measure an additional 20 % 
load, allowing for the max load to be 36 (kgf). In each of these cases, the material powder began 
to separate from its hydration solution due to the injection force. The third 1-cc injection syringe 
of HydroSet™ and Norian™ could not be injected due to material curing. AccuFill®, 
StrucSure™ and Simplex™ were all 3 cc materials able to be injected. AccuFill® and 
StrucSure™ showed similar mean injection forces for syringe 1 and 2 but were statistically 
different (p < 0.001) with StrucSure™ being statistically higher in syringe 3. Additionally, 
AccuFill® showed (p < 0.001) lower maximum injection forces than all materials tested on all 
syringe runs except the first cc of StrucSure™ (Figure 9A). StrucSure™ did not interdigitate into 
the foam as readily, causing the force to increase over the course of injecting syringes. Although 





Simplex™ had a higher average mean injection force required to inject each cc. However, in 
comparison with StrucSure™ for all three cc runs, it was not different from Beta-BSM™ and 
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*Difference among groups (P<0.001)
† Difference in injection per group (P<0.001)








Figure 9. Injection force evaluation of some of the commercially available bone cement. A) 
Average Maximum Injection force (Kgf) showing how this BSMs differ from each other in the 
maximum force require to be deliver into a closed environment. Cerament, a CaP based cement, 
reaches the maximum force within the first 1cc injection and Beta BSM, Hydroset and Norian 
SRS, also CaP based cement, experience a phase separation of their component preventing then 
to deliver the third 1 cc syringe of BSMs. AccuFill and StrucSure, two CaP based cements, were 
the ones that required the lowest maximum injection force, with AccuFill reaching to 6 kgf in the 
third 1cc injection. *Group different from the others, † difference within the same group, ‡ 
difference across all syringes.  B) The Mean Injection Forces for each syringe run of all materials 
tested that were able to deliver all three syringes in the simulated trabecular bone. This Graph 
shows that average mean injection was lower in the CaP based cement in comparison to the 
PMMA cement (Simplex). The mean injection force was consistent with the Average Max. 
Injection force. AccuFill requires the lowest injection force when deliver into a closed area. 
*Group different from the others, † difference within the same group, ‡ difference across all 
syringes.   
 
3.2 Measurements for Net Weight 
To determine the actual mass of cement delivered into the simulated cancellous bone, the 
empty foam was measured pre and post injection. In addition, the samples were measured harden 
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*Difference among groups (P<0.001)
† Difference in injection per group (P<0.001)






during the drying process. As expected, the hydrophobic cements lost the least amount of water 
and the CaP-based (hydrophilic) cements lost the most water (Table 2).  
In the lyophilized type of cement, hardened weights were used to determine the 
hypothetical weight increase in the experimental blocks when 3 cc of cement was introduced. 
However, several materials began to extravasate from the entry hole around the sides of the 
cannula with the removal of the needle from the injection site. In these cases, while we were able 
to inject the material, it did not stay in the model fracture site (Figure 14). The extravasated 
BSMs were removed from the top of the block prior to lyophilizing and determining the final 









Loss of Water 
% 
AccuFill® 1.78 ± 0.03 1.34 ± 0.03 1.24 ± 0.02 29.97 
Beta-BSM™ 1.34 ± 0.18 1.07 ± 0.16 0.87 ± 0.11 34.98 
Cerament™ 2.04 ± 0.09 1.71 ± 0.07 1.70 ± 0.07 16.90 
HydroSet™ 1.98 ± 0.08 1.60 ± 0.07 1.55 ± 0.07 21.77 
Norian™ SRS 1.69 ± 0.01 1.18 ± 0.01 1.17 ± 0.01 31.14 
Pro-Dense® 2.02 ± 0.05 1.76 ± 0.05 1.76 ± 0.05 13.14 
StrucSure™ 1.71 ± 0.17 1.21 ± 0.12 1.20 ± 0.12 29.65 
Simplex™ P 1.09 ± 0.14 1.06 ± 0.14 1.06 ± 0.14 2.10 
Loss of water was calculated based on change in weight from wet past to lyophilize hardened. 
Table 2:  Weights of each material at three stages of the drying process. This measurement 
shows that the hydrophobic cement, PMMA, was the one that lost the least among of water in the 
drying process (~2%). Also, AccuFill and StrucSure, two CaP based cement, lost the greater 
among of water, reaching up to (~29%) water lost. 
 
The net dry weights of the BSMs present were calculated. Any BSMs material that 
extravasated from the path of the channel created for the cannula (Figure 10) were removed from 
the top of the block prior to drying and weighing. In the samples in which material extravasated 
from the injection site, a small amount of foam may have been removed along with the BSMs. 





Simplex™ at 2.24 g and StrucSure™ at 1.47 g were statistically different than the AccuFill® but 
were also different from all other materials tested.  The remaining materials had an average dry 
weight of less than 1.00 g (Figure 10). 
Using dry weight measurement, we were able to determine that the entire (101 %) expected 
mass of AccuFill® remained inside the block (4.07 g injected vs. 4.02 g expected) and was 
statistically different than all of the other materials. 29.6 % of Simplex retro-ejected from the 
insertion point, found inside the block was only 2.24 g of the expected 3.18 g. StrucSure™ 
similarly saw some extravasation where of the 3.60 g expected after having 3 cc injected, the 
average was only 1.47 g (41%) inside the block. The remaining products showed < 5 % of the 
expected material inside the foam. The weight findings for Norian™ were slightly negative due 
to a small amount of the foam being removed along with the extravasated BSMs (Figure 10). All 
the BSMs tested differently under the same conditions. BSMs need to be classified so that 










Figure 10. Net weights measurements of the common commercially available bone cement that 
were tested. Data is presented as the mean and standard deviation with a p<0.01 for significant 
difference. AccuFill, StrucSure and Simplex were significantly different from the rest of the 
sample, having AccuFill delivering the greater mass of the BSMs into the simulated cancellous 
bone.  
 
3.3 Micro-CT Scan of commercially available bone cements 
 
After seeing all the variations in both the injection force and the weight measurements, a 
question arose, what is the interaction between the BSMs and the simulated trabecular bone? To 
answer this question, a micro-CT analyses was performed. The analysis confirmed the 
observations seen during the mechanical testing of the injection for the commercially available 
bone cement. Only AccuFill®, StrucSure™, and Simplex™ demonstrated a notable volume 
injected into the block and interdigitated into the architecture (Figure 11). The computational 
analysis of the micro-CT reconstructions were able to provide the fraction of space occupied by 
the BSMs (CV) to total volume of the foam block (TV) thereby yielding the percentage of BSMs 
(CV/TV). The average volume of material was: AccuFill® 12.7 %, StrucSure™ 5 %, Simplex™ 
























different (p < 0.001) than all other materials. Simplex™ and StrucSure™ were not statistically 
different from each other but were statistically different from all the other materials (Figure 12). 
This information was correlated to the weight measurements (figure 13), showing that there was 
a good correlation both in trend and in the weight measure in all the samples. 
 
Figure 11. Representative micro-CT reconstructions of each BSMs material. Micro-CT image of 
the foam samples both as a whole and cut at the zero-plane. It shows the different pattern 
behavior of the BSMs in the simulated cancellous bone. AccuFill is shown to have the best 





Figure 12. Commercially available BSM volume per tissue/foam volume (CV/TV). It illustrate 
that the volume present per sample has a similar trend as the net weigh measurements. 
 
 
Figure13. The coefficient of determination shows a good relationship for R^2=0.9968 between 
the weight measured and the cement volume that was evaluated with the Micro CT scan. This 
confirms the accuracy of our measurements, were the mass injected distribute uniformly in the 
intended space. 
 
3.4 Cadaveric Samples 
In order to validate our testing system, human cadaveric samples were utilized. Only 
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injection force and maximum injection force, there were no statistical differences between the 
cadaveric samples and the foam samples for either material (data not presented here). In addition, 
the micro CT image shows similar behavior with the AccuFill covering most of the area of the 
bone sample and Beta BSM covering just a portion of the sample (Figure 14). This behavior 
agrees with what was seen in the simulated trabecular bone. 
 
Figure 14.Micro CT images of humans’ cadaveric samples that were injected with either 
AccuFill or Beta BSM. This image validates the behavior that was seen in the injection pattern 
for the BSMs in the simulated trabecular bone. 
 
3.5 Mechanical testing of the injection force of bioactive fibers and glass beads in AccuFill 
at different wt%. 
 In an attempt to enhance the mechanical properties of AccuFill, different bioactive 
components were added to the cement. The addition of the bioactive glass fibers or glass beads 
to the AccuFill cement increased the level of the force needed in order to deliver the cement into 
the simulated cancellous bone material. However, this force was not statistically different from 
control. As the wt% of fibers or beads increases, so does the force needed to deliver the material 
inside the cannula (Figure 15).  This data is presented as the mean of the three injections per 






significantly different from the 53 um and 212-425 um beads particles. The lowest value is 2.92 
(Kgf), which is at little lower than the control, which is 3.32 (Kgf). This may be due to an 
unevenly distribution of the fibers in the cement. In addition, the glass beads behaved in a similar 
manner, but with a higher increase in the force needed to deliver the cement. This is more 
evident in the group with particles of larger sizes (212-425 um) in the 0.1% group, with 212-
425um being significantly different from the 53um samples in syringe 2. Also, the 1% 212-425 
um group was statistically different than the control, the fibers, and the 53um samples. In 
addition, the 212-425um was also significantly different from the fibers and the 53 um syringe 3 
on the 0.1% group. Furthermore, 212-425 um was statistically different from both the control 
and the 53 um for at 1% in syringe 3. 
At 10% wt, both 53um and 212-425um showed a decrease in the force needed to deliver 
the BSMs into the cannula in comparison to the fibers. The third injection in the fiber group was 
not able to be delivered completely into the cannula. The particles were not homogenous, most 
likely due to their difference in sizes. The maximum injection force for this group reached 12.13 
(Kgf), which was the overall highest force presented in the entire experiment. When comparing 
the 53um and the 212-425 um particles, the lowest amount of force needed to deliver the cement 
in the cannula was present at 1% and 10% for this group; this was also the overall lowest force 
present in the entire experiment. This was only significant in the 10% comparison to the fiber 
group. The smaller particles did not seem to add much to the viscosity of the cement, since the 
force required to deliver the cement was pretty close in value to the control group (Figure 15), 
and showed no significant difference. For the injection purpose, this particle makes a better 






Figure 15. Mean injection force evaluation of AccuFill bone cement with bioactive fibers and 
glass beads particles at different percentages. Data is presented as mean and standard deviation 
with (p<0.05) for significant difference. There was no significant difference between the groups 
tested. Nevertheless, there was significant difference with different %wt within the same groups 
as it is the case of fibers at 10%wt, which shows the required the greater amount of force to 
deliver the cement. Also, 53µm beads particles shows a consistency of force through the three 
different wt% tested, showing a significant lower injection force when compare to fibers and 
beads at 10%wt. 
3.6 Weight measurements of AccuFill with the bioactive components 
In order to establish a relationship between the forces needed to deliver the cement and the 
mass of cement delivered, weight measurements were applied. The presence of the fibers and 
beads seemed to cause an increase in the net weight of the AcuFill delivered into the simulated 
trabecular bone, but this weight was not significantly different from the control groups for either 
of the %wt (Figure 16). The addition of the fibers or beads to the AccuFill cement did not restrict 
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Figure 16.  AccuFill combine with different percentages of bioactive fibers or beads. Data is 
presented as the mean and standard deviation with a 𝑝<0.05 for significant difference. The net 
mass deliver into the simulated trabecular bone was consistent (p>0.001) in all the wt% tested.  
 
3.7 Micro-CT scan of AccuFill combine with bioactive fibers and beads+ 
 
In order to validate the weight measurement results, a micro-CT analysis was applied. The 
micro CT image shows that the addition of bioactive fibers or glass beads to AccuFill has 
apparent effect in the interdigitation of the Accufill cement and the foam material (Figure 17). 
The data shows that there is no statistical difference among the different groups that were 
compared except for the 53 um. In addition, the 53um group at 1% was significantly different 
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Figure 17. Representative micro-CT reconstructions of AccuFill bone cement with bio-glass 
fibers and beads particles at different percentages. Micro-CT image of the foam samples both as 
a whole and cut at the zero-plane. The image shows a consistent flow pattern behavior 
throughout all the samples tested. Only the larger particles at the greater wt% shows an 
accumulation of particles near the center of the simulated trabecular bone were the cannula 
should have ended. Overall, the material was able to interdigitated independently of the wt% and 









Figure 18. AccuFill bone cement with bio-glass fibers and beads at different percentages volume 
per tissue/foam volume (CV/TV). Data is presented as mean and standard deviation with 
(p<0.05) for significant difference. The Volume of AccuFill was not significantly different 
among the different bioactive components (p<0.05), but was significantly lower for the 53µm 
particles in the 0.1wt% group. 
3.8 Compressive Strength  
To determine if the bioactive components have an effect in the AccuFill cement, a 
compressive strength analysis was applied. The bioactive components, either bioactive fibers or 
glass particles, were subjected to a compression test in order to evaluate the mechanical 
properties (Figure 19). Adding the bioactive fibers to the AccuFill showed an increase in the 
compressive strength of the cement with an addition of 10% wt increasing up to 25.92 MPa. This 
is an increase of 15% in compressive strength when compared to control.  In addition, the lower 
weight percentage did not affect the compressive strength, showing no significant difference 
from the control with p<0.05. Also, the bioactive beads seem to decrease the compressive 
strength when compared to the fibers at 10%. Both 53um and 212-425um were statistically 
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compressive strength increased to 3.6% when compared to the control, but the 10 %wt sample 
decreased by 31%; but this was not statistically different. Furthermore, the larger particles at 
1%wt increased the strength only to 1.33% when compared to the controls. Also, the 10%wt 
samples for both small and large particles decreased the amount of stress load that the samples 
can withstand; this may have been caused by an increase in the set up time of the cement due to 
the additions of the particles that may not have set within the 2 hours of incubation. This could 
be the reason why smaller particles at 10%wt showed lower compressive strength. A significant 
difference was seen between the 0.1%, 1% and the 10% groups. One can infer that the proper 
distribution of the components play an important role in the mechanical properties of the product 









Compressive Strength of AccuFill Cement with Bioactive fiber and glass beads
Figure 19. Compressive strength test measuring the stress at maximum load (MPa). Effect of 
%wt of bioactive fibers and beads in AccuFill cement. Data presented as mean and standard 
deviation for n=5. Data is presented as mean and standard deviation with (p<0.05) for significant 
difference. The addition of the bioactive components did not enhance the compression strength 
significantly when compare to control but a difference was present in the fiber group at 10 %wt 
with a decrease in the compression strength. 
 
3.9 SEM Microscopy 
To obtain a qualitative analysis of the Accuffil bone cement combined with the bioactive 
fibers and glass beads, a SEM microscopy was used. This evaluation showed how the 
consistency of the cement changed as the percentage of fibers or beads was increased from 
0%wt, or control, up to 10%wt (Figure 20). Also, these images confirm that the components 
were not homogeneously distributed in the mixture. For example, there were no visible 
differences between the amount of fibers presented in the 0.1% or 1% groups. Meanwhile, the 
10% group was expected to contain a high quantity of fibers but this was not visible in the 





absorbing all the liquid media and making a mesh of fibers. Nevertheless, what was evident was 
that the increase in sizes and quantity of bioactive glass beads changes the set up structure of the 
cement by providing a more solid phase of cement. The ranges in sizes of the particles were able 
to fill the porous texture, providing more compact looking cement.  
 
Figure 20. SEM image of AccuFill combined with different percentages of bioactive fibers 
and beads. The image shows a trend in the increase of particles by sizes and wt%. The larger 
particles changed the apparent surface porosity into a more solid looking cement.  
 
 
CHAPTER 4: Discussion 
The compressive strength of trabecular bone is highly dependent on the location, the apparent 
density, and the bone mineral content [18,45,56]. Bone BSMs are widely used in order to 
reconstruct and add stability to the affected areas where the trabecular bone is compromised by 
disease state. The ideal material would also have strength properties similar to the surrounding 
trabecular bone and would be able to be remodeled over time without affecting the mechanical 





Human joints are susceptible to degeneration from disease, trauma, and long-term repetitive 
use. In the knee, the cartilage and subchondral bone are affected by a variety of diseases such as 
traumatic osteochondral defects, osteochondritis dissecans, osteonecrosis, and osteoarthritis [18]. 
A growing understanding of the pathophysiology of knee osteoarthritis has led researchers to 
redefine osteoarthritis as a degeneration of both the articular cartilage and subchondral bone. 
Bone marrow lesions are micro-trabecular fractures that occur in osteoarthritis condition 
rather than osteoporotic bone, and are related to impair healing potential. When patients do not 
exhibit severe degenerative changes in the knee, one possible treatment option to alleviate pain is 
to treat the underlying defects of the subchondral bone by a procedure described as 
Subchondroplasty® [12]. The goal of the procedure is to fill the bone lesion area with bioactive 
BSMs, which can be remodeled into healthy bone over time. For this type of procedure, one 
should select BSMs that can not only fill a closed void, but also provide the strength needed to 
sustain a healthy bone structure. 
The most common commercially available bone material substitutes were tested to compare 
their ability to inject into a closed environment under pressure. Although a limitation of our 
study is that foam block is not identical but similar to trabecular bone, the foam block model was 
shown by comparison to cadaveric samples to be a valid model to compare commercially 
available bone BSMs in a closed structure. The test model was foam because the quality and 
structure of cadaveric samples can vary greatly and innately have too much variability to 
compare between BSMs materials. The comparative analysis shows that the eight materials 
tested performed differently both in the volume able to be introduced and the material’s ability to 
interdigitate into the architecture. Although all the materials are understood as injectable BSMs, 





Beyond the basic ability to inject into the bone, the amount of material able to be introduced 
is important because the BSMs must stabilize the fracture area or support the void space during 
the healing process. In this model, we defined a desired injection amount of 3 cc of material, and 
only AccuFill® was observed to have attained the desired volume of material implanted inside 
the foam (Figure (9A-9B)). 
The amount of material desired changes with the defect size. Other than AccuFill®, all other 
materials either reach the maximum injection force of our apparatus or showed increasing 
injection force required to implant each subsequent cc. Therefore, it would be reasonable to 
assume that with greater defect size that the maximum injection force would continue to increase 
with desired amount of implanted BSMs.  
One important aspect to take into account is that the delivery method used to deliver the 
BSMs into the simulated trabecular bone differs from the syringe used in the clinical protocol. A 
1 cc syringe was utilized but in the clinical setup, a 3 cc syringe is more likely to be used 
depending on the defect sizes. This change in the syringe sizes may have contribute to the 
behavior seen in Cerament™, Norian™ SRS and Hydroset™, were the third syringe was not 
able to deliver the intended material. This behavior may have been attributed to a shear 
thickening in the material as it was intended to travel along a small orifice. The setup time of 
these materials ranges between 2 and 4.5 minutes. This did not play a factor in the delivery 
behavior of the materials, because the setup time of StrucSure™ and Simplex™ is 2 minutes and 
they were able to deliver the volume of BSM in all three injections (Figure 9A).  
In an attempt to further understand the behavior of these cements and to enhance the 
mechanical properties to a more suitable material for the subchondral bone, AccuFill was utilized 





injection is divided into two physical processes: cement delivery and “infiltration” [16]. This is 
important because it allows the understanding of the force required to be injected and how it 
interacts with the native tissue. The addition of the fibers and beads did not significantly change 
the force required to deliver the bone cement into the simulated cancellous bone (Figure 15). A 
micro CT evaluation was applied to visualize the behavior of the construct (AccuFill/ fibers or 
AccuFill/beads). The behavior observed was fairly similar in all the groups tested except for 
beads of sizes ranging 212-425µm at 10%, were the image shows a non-homogenous distribution 
of the partials (Figure 17).  Tang et al, reported that the rough surface of the broken particles 
make then stick to each other [23]. This cam explains why the larger particles at the greatest 
percentage were not able to disperse homogenously in the mixture, more particles means less 
distance between each particles and higher attraction for each other rough surface. 
Further investigation will be required to understand the mechanical properties of the BSMs 
over time in a closed environment. However, this study demonstrated that in a closed fracture 
environment, AccuFill® performed superior to the other BSMs tested: with the lowest injection 
forces, the highest volume injected, the greatest area covered by material injected, and finally 
without an exothermic reaction. CaP cements are known for their phase separation when subject 
to high injection pressure, this is known as “filter pressing.” This behavior depends on the 
geometry of the cannula as well as the cement characteristic [16]. This behavior was seen when 
the commercially available cements were compared. Even though most of the cement tested in 
the first part of this paper were CaP based, their overall composition was different and this was 
visible in the amount of cement delivered into the simulated cancellous bone, as shown in the 
micro CT images (Figure 12). This phase separation was not present in the samples that were 





14). The enhanced cement continued to be injectable, “injected out of the syringe independently 
of the force”, the composition did not vary [16]. On the contrary, the smaller particles (53 µm) 
seen to enhance the flowability by slightly decreasing the force required to deliver the material 
into the simulated trabecular bone. Most likely this is due to the particles filling the porosity in 
the BSM, decreasing air bubbles hence decreasing the resistance when pushing the cement into 
the sawbones.  
Also, the “flowability” pattern within the foam sample shows that AccuFill® was able to 
navigate the void space without damaging the structure with the applied force. The results show 
that the addition of any of the components, the fibers or the beads, has an increase in the 
compressive strength up to a certain limit. At 10% wt (Figure 19), shows that the particle size 
and shape may influence those mechanical properties of the material. The 53 um particles are 
very similar in texture to the solid phase of the CaP cement; this could explain why at 10% this 
group was significant different from the others. Often in literature, one of the concerns during the 
mechanical enhancement of the CaP is that an increase in the strength of the material can affect 
the excellent bioactivity properties of the cement [3]. Yu et al. (2013) evaluated the compressive 
strength of CaP cement combined with bioactive glass components at 10% and 20% and found 
that at the 7 days of the incubation period there is an increase in the strength as the ratio of 
bioactive glass increases. The compressive strength reaches 26 MPa at 1 day and 40 MPa at 7 
days [29]. In the present study, the compression strength was evaluated after 2 hrs from the 
injection.  The results showed that after this time the composite can reach between 12.5 MPa to 
35 MPa depending on the composition. Fibers showed the greatest increase in the compressive 
strength when compared to the glass beads particles. Perhaps if toughness evaluation was applied 





of this construct be evaluated because this will provide a more complete evaluation of how this 
construct will behave in vivo, especially in a load bearing region. The toughness evaluation 
provides information about how the material absorbs energy and how it deforms under loading. 
4.1 Future Approach 
Based on our findings, additional test would be required to evaluate the effect of the 
bioactive component in the CaP bone substitute material. First, the setting time of the construct 
needs to be monitored in order to identify any changes in the physical properties of the cement. 
Also, it is important to determine what it is the effect of the syringe sizes in the cement flow 
ability, since it may be experiencing some shear thickening during the delivery method. In order 
to evaluate this behavior, I recommend that the rheological properties of the cement be evaluated 
with the addition of the bioactive fibers and beats particles.  Furthermore, since we did not obtain 
a positive result during the compressive analysis that was done in this components, I recommend 
that fracture strength and fracture toughens be evaluated instead. This will provide better 
measurements for the type of enhancement that was intended during the present study.  It is of 
great importance not only to know the compressive strength of the material but also how the 
cracks propagates in the sample can provide a more constructive mechanical analysis of the 
structural composition. In addition, since this material is intended to be used in a load bearing 
region, would be equally important to know how this material resists cracks. One way that this 
could be evaluated is by the analysis of stress energy or by evaluating the stiffness, since an 
increase in crack propagation relates to a decrease in stiffness.  These parameters can be 
evaluated by a nano-indentantion test in the construct. 
Furthermore, additional test would be required to evaluate degradation properties of this 





deliver the cement, the pressure required to deliver each syringe (using an instrument with force 
and displacement transducer), and an evaluation of the infiltration by the use of the Darcy law. 
Since CaP cement is dependent in composition and particle sizes, it would be important to 
evaluate the biological response of the osteoclasts cells towards the different percentages of the 
bioactive glass fibers or beads. Also, the biological activities can help to evaluate if the 
integration of these particles (bioactive glass fibers or beads) have an effect in the dissolution of 
the cement in the physiological solution and the cell-mediated response (phagocytosis). Another 
important aspect to consider, is the osteoinduction kinetics, this will allow us to determine the 
rate of bone deposition due to the cement. It takes 3 to 12 months for a CaP cement to 
demonstrate osteoconduction [3]. Since this bioactive fiber and bead promotes bone growth, 
what would be their effect in the osteoprogenitor cells when combined with the calcium cement? 
CHAPTER 5. Conclusions 
The “injectability” of classic cements were always considered to be a function of viscosity 
and could easily be manipulated to achieve the desired defect fill. This investigation of the 
performance of materials in a small void model under pressure has shown that not only classic 
cement, PMMA, but also most commercially available BSMs materials are not directly governed 
by viscosity but are more related to their chemical composition. Future material development 
would need to focus not only on open, large bony voids, but also smaller applications where 
interdigitation is crucial. The addition of bioactive fibers to the CaP may be an alternative 
solution for the enhancement of the mechanical properties of this cement, especially for its 
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